Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CHRS will decline by -1.23% over the next 2 Weeks and hit $1.45 by Tuesday, August 4, 2026. In that time frame, CHRS's share price is expected to range between $1.35 and $1.55.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Aug 4, 2026 | 1.35 | 1.45 | 1.55 |
| Aug 3, 2026 | 1.36 | 1.46 | 1.55 |
| Jul 31, 2026 | 1.36 | 1.46 | 1.57 |
| Jul 30, 2026 | 1.37 | 1.47 | 1.57 |
| Jul 29, 2026 | 1.34 | 1.45 | 1.54 |
| Jul 28, 2026 | 1.35 | 1.45 | 1.55 |
| Jul 27, 2026 | 1.36 | 1.45 | 1.56 |
| Jul 24, 2026 | 1.36 | 1.46 | 1.56 |
| Jul 23, 2026 | 1.37 | 1.47 | 1.57 |
| Jul 22, 2026 | 1.34 | 1.44 | 1.54 |
CHRS shares fell -0.34% in Wednesday, July 22, 2026's trading session, dropping from a previous close of $1.47 to move at $1.47. The stock demonstrated notable intraday movement (see CHRS's key stats for a full breakdown), fluctuating between $1.41 and $1.49, a +5.32% trading range. While recent weeks have seen some volatility, CHRS has managed to secure a -11.21% drop over the past 2 weeks. The downward price movement was accompanied by increased trading volume, with approximately 373.28K shares changing hands, 7.85K more than the previous session. This amounted to $546.86K in total market activity.
Will CHRS Continue Its Upward Trend?
According to analyst ratings and projections for CHRS, Coherus Oncology, Inc. shares are anticipated to increase by +5.74%, potentially reaching $1.55 per share by August 4, 2026. Short-term technical indicators currently suggest a neutral sentiment for CHRS. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 13 positive trading days within the past 30 sessions. Based on the CHRS stock forecast, now is a good time to buy CHRS stock because its current trading price is +0.90% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on CHRS covering social and institutional perspectives.
CHRS Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CHRS's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 47.38% to 48.59%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 47.86%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 49.26%, maintains a neutral outlook for the long term. Insights into CHRS's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Coherus Oncology Short-Term Forecasts
CHRS Forecast For Next 5 Days
Our algorithm anticipates Coherus Oncology (CHRS) stock could hit $1.44 by Jul 29, 2026. This represents a -1.95% fall from today's price, following a -6.06% change over the past five days.
CHRS Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Coherus Oncology, Inc. (CHRS) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $1.45, which would mean a -1.02% decrease from the current price of $1.47. Projections for this period range from a high of $1.63 to a low of $1.28.
CHRS Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Coherus Oncology's price over the next three months point to a rise. CHRS stock is expected to peak at $5.60 on Aug 03, 2026 before potentially dipping to $3.42 on Oct 01, 2026. On average, CHRS is likely to trade around $4.84 in the coming 90 days.
Coherus Oncology Stock Forecast 2025
Based on our predictive models, Coherus Oncology (CHRS) is expected to trade between $2.85 and $5.90 throughout 2026. This would result in an average price of $4.49, potentially offering investors a +206.48% return from current levels.
Coherus Oncology, Inc. Monthly Forecast 2026–2027
July 2026
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in July 2026. The price is predicted to move between $4.78 and $5.50, settling at an average of $5.13. This could translate to a +250.17% gain.
August 2026
Based on current market signals, Coherus Oncology, Inc. is projected to trend august 2026. We forecast a trading range from $4.87 to $5.60, with a likely average price of $5.17. Investors could expect a potential return of +252.90%.
September 2026
Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in September 2026. The expected range spans $3.53–$5.52, with an average target of $4.84. This represents a positive outlook and a possible gain of +230.38%.
October 2026
Analyzing established trends, Coherus Oncology, Inc. looks set to move in October 2026. Projections place the stock between $3.42 and $5.07, averaging around $4.19. This suggests a +186.01% gain from current levels.
November 2026
Market indicators suggest Coherus Oncology, Inc. could experience notable changes during November 2026. Prices could fluctuate within $2.85 to $4.01, with a midpoint forecast of $3.42. The stock might deliver a +133.45% gain.
December 2026
Forecasting for December 2026, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $3.41 and $5.90, averaging $4.55. This signals a positive trajectory with potential returns around +210.58%.
January 2027
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in January 2027. The price is predicted to move between $3.62 and $6.11, settling at an average of $5.29. This could translate to a +261.09% gain.
February 2027
Based on current market signals, Coherus Oncology, Inc. is projected to trend february 2027. We forecast a trading range from $2.92 to $5.66, with a likely average price of $4.80. Investors could expect a potential return of +227.65%.
March 2027
Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in March 2027. The expected range spans $2.52–$5.20, with an average target of $4.34. This represents a positive outlook and a possible gain of +196.25%.
April 2027
Analyzing established trends, Coherus Oncology, Inc. looks set to move in April 2027. Projections place the stock between $2.55 and $6.10, averaging around $5.20. This suggests a +254.95% gain from current levels.
May 2027
Market indicators suggest Coherus Oncology, Inc. could experience notable changes during May 2027. Prices could fluctuate within $1.64 to $5.97, with a midpoint forecast of $4.79. The stock might deliver a +226.96% gain.
June 2027
Forecasting for June 2027, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.93 and $5.10, averaging $4.38. This signals a positive trajectory with potential returns around +198.98%.
July 2027
According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in July 2027. The price is predicted to move between $0.81 and $5.28, settling at an average of $4.14. This could translate to a +182.59% gain.
CHRS's history of dividends and stock splits also plays a role in long-term investor confidence.

